[125I] 2-(2,3-diiodo-4-hydroxyphenyl)-1,3,4-oxadiazole was synthesized (48% yield) and acid-hydrolyzed in situ with direct derivatization with p-nitro benzaldehyde to obtain the required 125I hydrazone (89% yield). A blood clearance kinetic study was performed on the 125I oxadiazole in a Sprague-Dawley rat and a biphasic behaviour was obtained. This study shows that 125I oxadiazole has potential to be metabolically stable and enough to allow imaging and tracking for a minimum of 2 h, making it a viable option for in situ indirect labeling of carbonyl containing macromolecules and keto steroids.
No takes yet. Share an insight, caveat, or question.
Shabsoug et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: